➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

DUONEB Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Duoneb, and when can generic versions of Duoneb launch?

Duoneb is a drug marketed by Mylan Speciality Lp and is included in one NDA. There is one patent protecting this drug.

This drug has fifteen patent family members in eight countries.

The generic ingredient in DUONEB is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.

US ANDA Litigation and Generic Entry Outlook for Duoneb

There is one tentative approval for the generic drug (albuterol sulfate; ipratropium bromide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for DUONEB
International Patents:15
US Patents:1
Clinical Trials: 2
Formulation / Manufacturing:see details
DailyMed Link:DUONEB at DailyMed
Drug patent expirations by year for DUONEB
Recent Clinical Trials for DUONEB

Identify potential brand extensions & 505(b)(2) entrants

University Hospitals Cleveland Medical CenterPhase 1
Shin-hwar WuN/A

See all DUONEB clinical trials

Paragraph IV (Patent) Challenges for DUONEB
Tradename Dosage Ingredient NDA Submissiondate
DUONEB SOLUTION;INHALATION albuterol sulfate; ipratropium bromide 020950

US Patents and Regulatory Information for DUONEB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Speciality Lp DUONEB albuterol sulfate; ipratropium bromide SOLUTION;INHALATION 020950-001 Mar 21, 2001 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.